The patient is waiting

From innovation to validation to commercialization, we're applying key insights learned over the last 20+ years to speed the development of promising new therapies. Moving forward, we're expanding our collaborations to more quickly meet the needs of today’s patients.

Innovation starting with strong platforms

Heat shock proteins (HSPs) and QS-21 Stimulon® adjuvant (QS-21) are potential engines for breakthrough immunotherapies.

Validation pressing forward with leaders

Agenus continues to advance its discoveries through the clinic. We have completed 15 phase 1/2 and 3 clinical trials with our Prophage Series vaccine candidates, consistently generating signals of anti-tumor activity. To help speed our progress with Prophage and our other product candidates, we continue to build strong relationships with leading universities like UC San Francisco and UW Seattle as well as major pharmaceutical companies like GSK and Janssen Alzheimer Immunotherapy that complement our internal efforts.

Commercialization striving to deliver on our promise to patients

All around the world there are millions of patients who could potentially benefit from our medical breakthroughs.